作者：李雪晶，牛玉秋，陈艳

单位：

辽宁省盘锦市中心医院药局

Units：

Department of Pharmacy, Panjin Central Hospital, Panjin 124010, China

关键词：

心绞痛; 参芍胶囊; 心肌功能; 斑块稳定性;

Keywords：

Angina pectoris; Shenshao capsules; Myocardial function; Plaque stability

CLC：

DOI：

10.12114/j.issn.1008-5971.2023.00.095

Funds：

辽宁省自然科学基金指导计划项目（2019-ZD-0401）；

摘要：

目的 探讨参芍胶囊治疗心绞痛的效果，并分析其对患者心肌功能及动脉粥样硬化斑块稳定性的影响。方法 选取2020年3月至2021年12月盘锦市中心医院收入的心绞痛患者104例进行前瞻性研究，通过简单随机化法将患者分为试验组（n=52）与参照组（n=52）。参照组进行常规治疗，试验组在参照组基础上服用参芍胶囊。两组均治疗4周。比较两组治疗效果和治疗前后心肌功能指标{血清指标[P选择素糖蛋白配体1(PSGL-1)、P选择素（PS）、肌钙蛋白T(TnT)]、临床指标（心肌缺血总负荷、心肌缺血持续时间、24 h内心绞痛发作次数）}、斑块稳定性指标{影像学指标（斑块体积、斑块数量）、血清炎性因子[基质金属蛋白酶9(MMP-9)、超敏C反应蛋白（hs-CRP）]}及安全性指标（不良反应发生情况）。结果 试验组治疗效果优于参照组（P<0.05）。两组治疗后血清PSGL-1、PS、TnT分别低于本组治疗前，且试验组低于参照组（P<0.05）。两组治疗后心肌缺血总负荷、24 h内心绞痛发作次数分别少于本组治疗前，心肌缺血持续时间分别短于本组治疗前，且试验组治疗后心肌缺血总负荷、24 h内心绞痛发作次数少于参照组，心肌缺血持续时间短于参照组（P<0.05）。两组治疗后斑块体积分别小于本组治疗前，斑块数量分别少于本组治疗前，且试验组治疗后斑块体积小于参照组，斑块数量少于参照组（P<0.05）。两组治疗后血清MMP-9、hs-CRP分别低于本组治疗前，且试验组低于参照组（P<0.05）。两组不良反应发生率比较，差异无统计学意义（P>0.05）。结论 参芍胶囊可有效治疗心绞痛，促进患者心肌功能恢复，提高动脉粥样硬化斑块稳定性，具有临床应用价值。

Abstract：

Objective To investigate the effect of Shenshao capsule in the treatment of angina pectoris and analyzeits influence on myocardial function and the stability of atherosclerotic plaque. Methods A prospective study was conductedon 104 patients with angina pectoris from Panjin Central Hospital from March 2020 to December 2021. They were divided intoexperimental group (n=52) and control group (n=52) by simple randomization method. The control group received conventionaltreatment, and the experimental group received Shenshao capsule on the basis of the control group. Both groups were treated for4 weeks. The therapeutic effect, myocardial function indexes {serum indexes before and after treatment [P-selectin glycoproteinligand-1 (PSGL-1) , P-selectin (PS) , troponin-T (TnT) ] , clinical indexes (total myocardial ischemic load, duration of myocardialischemia, number of angina attacks within 24 h) } , plaque stability indexes {imaging indexes (plaque volume, plaque number) ,serum inflammatory factors [matrix metalloproteinase-9 (MMP-9) , hypersensitive C-reactive protein (hs-CRP) ] } before and aftertreatment and safety indicators (incidence of adverse reactions) were compared between the two groups. Results The therapeuticeffect of experimental group was better than that of control group (P < 0.05) . Serum PSGL-1, PS and TnT in both groups aftertreatment were lower than those before treatment respectively, and serum PSGL-1, PS and TnT in experimental group aftertreatment were lower than those in control group (P < 0.05) . The total myocardial ischemic load and the number of angina attackswithin 24 h in both groups after treatment were less than those before treatment respectively, and the duration of myocardialischemia in both groups was shorter than that before treatment, and the total myocardial ischemic load and the number of anginaattacks within 24 h after treatment in experimental group were less than those in control group, and the duration of myocardial ischemia was shorter than that in control group (P < 0.05) . The plaque volume and number of the two groups after treatment wereless than those before treatment respectively, and the plaque volume and number of the experimental group after treatment wereless than those of the control group (P < 0.05) . After treatment, serum MMP-9 and hs-CRP in both groups were lower than thosebefore treatment respectively, and serum MMP-9 and hs-CRP of the experimental group were lower than those of the controlgroup (P < 0.05) . There was no significant difference in the incidence of adverse reactions between the two groups (P > 0.05) .Conclusion Shenshao capsule can effectively treat angina pectoris, promote myocardial function recovery of patients, improvethe stability of atherosclerotic plaque, and has clinical application value.

ReferenceList：